[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352975-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352975-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-promise-of-immunotherapy-in-the-treatment-of-sarcoma-a-state-of-the-art-review-of-practice-changing-research-and-future-directions","The promise of immunotherapy in the treatment of sarcoma - A state-of-the-art review of practice changing research and future directions","","Soft-tissue sarcoma presents distinctive therapeutic obstacles driven by rarity and marked histologic heterogeneity. Across subtypes, differences in genetic features, tumor microenvironment, recurrence behavior, and treatment response shape clinical management. Localized disease is managed primarily with surgical resection, while systemic therapy is used for high-risk and metastatic cases. Immunotherapy has been linked to an “immune-cold” phenotype, though combination strategies, neoadjuvant approaches, adoptive cellular therapies, and emerging biomarkers are actively investigated to improve checkpoint inhibitor efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-promise-of-immunotherapy-in-the-treatment-of-sarcoma-a-state-of-the-art-review-of-practice-changing-research-and-future-directions/352975/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-promise-of-immunotherapy-in-the-treatment-of-sarcoma-a-state-of-the-art-review-of-practice-changing-research-and-future-directions/352975.png","ImageObject",300,407,{"name":42,"@type":43},"Adam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is treating soft-tissue sarcoma challenging?","Question",{"text":63,"@type":64},"Soft-tissue sarcoma is difficult to treat because it is rare and highly heterogeneous across more than 100 histologic subtypes, which differ in genetics, tumor microenvironment, recurrence patterns, and treatment response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is soft-tissue sarcoma typically treated by stage?",{"text":68,"@type":64},"Localized disease is primarily treated with surgical resection, while systemic therapy is used for high-risk or metastatic cases; chemotherapy and radiation are also used for specific goals such as local control.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review say about checkpoint inhibitors in sarcoma?",{"text":72,"@type":64},"Checkpoint inhibitors show activity in certain sarcoma histologies, but responses are inconsistent overall, with metastatic STS characterized as predominantly “immune-cold” and checkpoint inhibition producing limited robust response rates.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352975,1790908379,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","REVIEW  \nThe promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions  \nNichita J. Kulkarnia, Ciara M. Kellyb, and Edmund K. Bartletta  \naDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; bDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \nABSTRACT  \nSoft-tissue sarcoma (STS) poses unique challenges to treatment due to its rarity and heterogeneity. Comprised of multiple histologies which, among other characteristics, differ in their genetic makeup, tumor microenvironment, recurrence patterns and therefore response to treatment, STS is treated primarily with surgical resection, with systemic therapy used in high-risk or metastatic cases. In the era of immunotherapy, STS has been characterized as predominantly immune-cold with few histologies demonstrating consistent robust responses to checkpoint inhibition in the metastatic setting. Strategies to improve checkpoint inhibition responsiveness, such as combination therapies and treatment in the neoadjuvant setting, have shown promise in certain sarcoma subtypes. Other immunotherapeutic approaches, such as adoptive cellular therapies, as well as development of reliable biomarkers for response to immune checkpoint inhibitors, are the subject of ongoing research in this field.  \nARTICLE HISTORY  \nReceived 6 February 2026 Revised 21 April 2026 Accepted 9 May 2026  \nKEYWORDS  \nSarcoma; immunotherapy; checkpoint inhibition; adoptive cellular therapy; vaccines; clinical trials  \nIntroduction  \nSarcoma is a group of rare, diverse malignancies comprising more than 100 histologic subtypes which remains challenging to treat. 1 Surgical resection is the preferred modality of treatment for localized soft tissue sarcoma (STS), with chemotherapy mainly used in advanced or metastatic cases and radiation used for local control. The various histologic subtypes of sarcoma differ in their local and distant recurrence patterns, which drive clinical decision-making regarding the prescription of local or systemic treatment. 1 The lack of effective systemic treatments available for treating soft-tissue sarcoma is underscored by the 10-y disease-specific death approaching 40% among patients with high-grade resectable disease.2 In the metastatic setting, the survival rate declines even further, reaching 30% at 5 y.3 One of the current front line chemotherapy regimens for unresectable or metastatic disease, comprising of doxorubicin and ifosfamide, demonstrates a response rate of roughly 20% with median survival of just over 1 y.4 This regimen has been in place since the 1980s.5 A second combination in use for STS, gemcitabine and docetaxel, has a response rate of 16% .6 Apart from chemotherapy, the tyrosine kinase inhibitor pazopanib and antineoplastic drug trabectedin have also been approved for use in STS, both with response rates less than 10% .7–10 The need for more effective therapies is evident, with the field of immunotherapy representing a key area of investigation for decades. This state-of-the-art review will summarize key findings in the field as well as works-inprogress and future directions.  \nMethods  \nDatabases such as Pubmed and the Cochrane library were searched for immunotherapy in sarcoma. Results were filtered for clinical trials in English, with emphasis given to studies in adult patients with soft-tissue sarcoma. References from relevant reviews and publications were also explored.  \nCONTACT Nichita J. Kulkarni  [kulkarn1@mskcc.org](kulkarn1@mskcc.org); [nichitakulkarni@gmail.com](nichitakulkarni@gmail.com)  Department of Surgery, Memorial Sloan Kettering Cancer  \nCenter, 1275 York Avenue New York, NY 10065, USA.  \n© 2026 The Author(s) . Published with license by Taylor & Francis Group, LLC.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([http://creativecommons.org/licenses/","cbCaiga9X8BLnb6H","https://ap.wps.com/l/cbCaiga9X8BLnb6H","pdf",490349,14,"English","# Introduction\n# Methods\n# Results\n## Immune checkpoint inhibitors demonstrate activity in certain sarcoma histologies","[{\"question\":\"Why is treating soft-tissue sarcoma challenging?\",\"answer\":\"Soft-tissue sarcoma is difficult to treat because it is rare and highly heterogeneous across more than 100 histologic subtypes, which differ in genetics, tumor microenvironment, recurrence patterns, and treatment response.\"},{\"question\":\"How is soft-tissue sarcoma typically treated by stage?\",\"answer\":\"Localized disease is primarily treated with surgical resection, while systemic therapy is used for high-risk or metastatic cases; chemotherapy and radiation are also used for specific goals such as local control.\"},{\"question\":\"What does the review say about checkpoint inhibitors in sarcoma?\",\"answer\":\"Checkpoint inhibitors show activity in certain sarcoma histologies, but responses are inconsistent overall, with metastatic STS characterized as predominantly “immune-cold” and checkpoint inhibition producing limited robust response rates.\"}]","The promise of immunotherapy in the treatment of sarcoma - A state-of-the-art review of practice changing research and future directions | PDF",1790102363,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2d23022d475a0502f023ff1c7c9867d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e3334c36c1d4c6c0e57566e80390507.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b30d2b48e669b8ae7d304c22d4ed978.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee1b6f807513cf0c509662e3224685a9.webp",980,1306]